Proposed Acquisition of Ellipses Pharma Limited

AI SummaryClose X

Wolfram Resources has signed a non-binding MoU to acquire the entire issued share capital of Ellipses Pharma and to relist the enlarged group on the Main Market (Commercial Companies); consideration is expected to be satisfied in new Wolfram ordinary shares and a proposed fundraise will accompany the relisting; detailed technical, financial and legal due diligence begins immediately with completion of the acquisition, fundraise and relisting targeted for early 2027; Ellipses contributes multiple clinical-stage oncology programmes including Phase 2 assets EP0031 and EP0062 and a Scientific Advisory Group of over 300 experts; the transaction remains conditional on satisfactory due diligence, agreed terms, FCA prospectus approval, shareholder approval, a Panel Rule 9 waiver and admission to the Official List.

Disclaimer*

Companies

Miotal Plc (MIO)
UK 100

Latest directors dealings